Associated Genetic Biomarkers
Uterine sarcomas most frequently harbor alterations in TP53, RB1, ATRX, MED12, and CDKN2A .
TP53 Mutation, TP53 c.217-c.1178 Missense, TP53 Missense, ATRX Mutation, and RB1 Loss are the most common alterations in uterine sarcoma .
There are 2 clinical trials for uterine sarcoma, of which 2 are open and 0 are completed or closed. Of the trials that contain uterine sarcoma as an inclusion criterion, 1 is phase 1 (1 open) and 1 is phase 2 (1 open).
ER and PR are the most frequent gene inclusion criteria for uterine sarcoma clinical trials .
Z-endoxifen, aspirin, and curcumin are the most common interventions in uterine sarcoma clinical trials.
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.